Abstracts tagged "Biologic agents"

Abstract Number: 1453 • 2017 ACR/ARHP Annual Meeting
Impact of Biological and Targeted Synthetic Dmards on Work in Patients with Chronic Inflammatory Arthritides : A Meta Analysis of Randomized Controlled Trials and Controlled Cohorts
Charlotte Traverson¹, Amandine Tubery¹, Charlotte Hua², Françoise Barchechath-Flaisler¹, Cédric Lukas³, Bernard Combe², Jacques Morel² and Cécile Gaujoux-Viala⁴, ¹Rheumatology, Nîmes University Hospital, Nîmes, France, ²Rheumatology, CHU Lapeyronie and Montpellier University, Montpellier, France, ³Rheumatology, CHU Lapeyronie and EA2415, Montpellier University, University of Montpellier, France, ⁴Rheumatology, Nîmes University Hospital and EA2415 Montpellier University, Nîmes, France
Background/Purpose: The addition of biological (b) and new targeted synthetic (ts) DMARDs agents in chronic inflammatory arthritides (CIAs) therapeutic strategies has improved the possibility of…
Abstract Number: 1826 • 2017 ACR/ARHP Annual Meeting
Secukinumab Achievement of Psoriatic Arthritis Disease Activity Score (PASDAS) Related Remission: 2-Year Results from a Phase 3 Study
Laura C Coates¹, Dafna D Gladman², Peter Nash³, Oliver FitzGerald⁴, Arthur Kavanaugh⁵, Lawrence Rasouliyan⁶, Luminita Pricop⁷, Kevin Ding⁷ and Corine Gaillez⁸, ¹Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ²Toronto Western Hospital, Toronto, ON, Canada, ³University of Queensland, Brisbane, Australia, ⁴St Vincent's University Hospital, Dublin, Ireland, ⁵UC San Diego School of Medicine, La Jolla, CA, ⁶RTI Health Solutions, Barcelona, Spain, ⁷Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁸Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Psoriatic arthritis (PsA) disease activity score (PASDAS) assessing multiple facets of PsA was demonstrated to distinguish treatment effect, perform better in statistical terms than…
Abstract Number: 2546 • 2017 ACR/ARHP Annual Meeting
Secukinumab Decreases Arterial Wall Inflammation in Patients with Peripheral Spondyloarthritis
Leonieke van Mens¹, Simone Verweij², Arno van Kuijk³, Erik Stroes² and Dominique Baeten¹, ¹AMC, Amsterdam Immunology and Rheumatology Center, Amsterdam, Netherlands, ²Vascular Medicine, Academisch Medisch Centrum, Amsterdam, Netherlands, ³Reade, Amsterdam Immunology and Rheumatology Center, Amsterdam, Netherlands
Background/Purpose: Patients with spondyloarthritis (SpA), a chronic inflammatory disease, have an increased cardiovascular risk, which is partly due to increased inflammatory activity in the arterial…
Abstract Number: 545 • 2017 ACR/ARHP Annual Meeting
Incidence of Infusion Reactions to Intravenous Golimumab: Results from a Prospective, Real-World Community Registry
Rafat Faraawi¹, Andrew Chow², Majed M M Khraishi³, Derek Haaland⁴, Milton F. Baker⁵, Cathy Tkaczyk⁶, Allen J Lehman⁷, Francois Nantel⁶ and Brendan Osborne⁶, ¹McMaster University, Hamilton, ON, Canada, ²Credit Valley Rheumatology, Mississauga, ON, Canada, ³Faculty of Medicine, Memorial University of Newfoundland, St John's, NF, Canada, ⁴Rheumatology, Clinical Immunology & Allergy, McMaster University, Barrie, ON, Canada, ⁵VIHA, Victoria, BC, Canada, ⁶Medical Affairs, Janssen Inc., Toronto, ON, Canada, ⁷Janssen Inc., Toronto, ON, Canada
Background/Purpose: Golimumab (GLM) is a monoclonal antibody targeting TNF-alpha, indicated for the treatment of adults with rheumatoid arthritis in combination with methotrexate (MTX). GLM-IV is…
Abstract Number: 1456 • 2017 ACR/ARHP Annual Meeting
Synergistic Reversal of Arthritis By Synoviocyte-Targeted Therapy and TNF Immunomodulation
Christian Secchi^1,2,3, Karen M. Doody², Mattias N. D. Svensson^2,4, Frances Humby⁵, Rebecca Hands⁵, Eugenio Santelli^1,2, Cristiano Sacchetti^2,6, Kuninobu Wakabayashi⁷, Dennis J. Wu⁸, Ardita Aliko⁹, Piotr Mydel^9,10, Tsuyoshi Kasama⁷, David L. Boyle¹¹, Francesco Galimi¹², Michel L. Tremblay¹³, Gary S. Firestein⁶, Costantino Pitzalis⁵, Stephanie Standford^8,14 and Nunzio Bottini^2,4, ¹Medicine, University of California San Diego, San Diego, CA, ²Cellular Biology, La Jolla Institute for Allergy and Immunology, La Jolla, CA, ³Medicine, National Institute of Biostructures and Biosystems, University of Sassari Medical School, Sassari, Italy, ⁴Department of Medicine, University of California San Diego, La Jolla, CA, ⁵Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Barts and The London, School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom, ⁶Medicine, University of California San Diego, La Jolla, CA, ⁷Div of Rheumatology, Showa University School of Med, Shinagawa-ku Tokyo, Japan, ⁸University of California San Diego, San Diego, CA, ⁹University of Bergen, Bergen, Norway, ¹⁰Clinical Science, Broegelmann Research Laboratory, Bergen, Norway, ¹¹University of California San Diego, La Jolla, CA, ¹²National Institute of Biostructures and Biosystems, University of Sassari Medical School, Sassari, Italy, ¹³Goodman Cancer Centre, McGill University, Montréal, QC, Canada, ¹⁴La Jolla Institute for Allergy and Immunology, La Jolla, CA
Background/Purpose: Despite the availability of immunosuppressive disease-modifying anti-rheumatic agents (DMARDs), many rheumatoid arthritis (RA) patients still fail to achieve remission. Fibroblast-like synoviocytes (FLS) are non-immunological…
Abstract Number: 1828 • 2017 ACR/ARHP Annual Meeting
Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Active Ankylosing Spondylitis: 2-Year Results from a Phase 3 Study
Karel Pavelka¹, Alan J. Kivitz², Eva Dokoupilova³, Ricardo Blanco⁴, Marco Maradiaga⁵, Hasan Tahir⁶, Alan Slade⁷, Yi Wang⁷, Susanne Rohrer⁸ and Brian Porter⁷, ¹Institute of Rheumatology, Prague, Czech Republic, Prague, Czech Republic, ²Altoona Center for Clinical Research, Duncansville, PA, ³MEDICAL PLUS s.r.o., Uherske Hradiste, Czech Republic, ⁴Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁵Centro de Investigación de Tratamientos Innovadores de Sinaloa, Culiacán, Mexico, ⁶Barts Health NHS Trust, London, United Kingdom, ⁷Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁸Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Secukinumab (SEC) improved the signs and symptoms of AS in 2 Phase 3 studies (MEASURE 1 and 2).1,2 Here, we present interim results through…
Abstract Number: 2743 • 2017 ACR/ARHP Annual Meeting
Requirement and Response Rates of Biologic Agents in Polyarteritis Nodosa (PAN)
Omer Karadag^1,2, Berkan Armagan², Abdulsamet Erden², Seerapani Gopaluni¹, Alper Sari², Sedat Kiraz² and David Jayne³, ¹Vasculitis and Lupus Clinic, Addenbrooke’s Hospital, University of Cambridge, Cambridge, United Kingdom, ²Hacettepe University Vasculitis Center (HUVAC), Ankara, Turkey, ³Vasculitis and Lupus Clinic, Department of Medicine, University of Cambridge, Cambridge, United Kingdom
Background/Purpose: Recent studies highlight the usefulness and necessity of biologic agents in the treatment of primary vasculitides. Evidence for the use of biologics in PAN…
Abstract Number: 598 • 2017 ACR/ARHP Annual Meeting
Efficacy of Ustekinumab in Psoriatic Arthritis Patients By Prior Treatment Exposure and Disease Duration
Arthur Kavanaugh¹, Soumya D. Chakravarty^2,3, G. James Morgan⁴, M. Isabel Apaolaza⁵, Shelly Kafka², Elizabeth C. Hsia^6,7, Michael Song⁷, Yin You⁷ and Iain B. McInnes⁸, ¹Medicine, University of California, San Diego, La Jolla, CA, ²Janssen Scientific Affairs, LLC, Horsham, PA, ³Drexel University College of Medicine, Philadelphia, PA, ⁴Janssen Scientific Affairs, LLC, Spring House, PA, ⁵Janssen Biologics BV, Leiden, Netherlands, ⁶University of Pennsylvania School of Medicine, Philadelphia, PA, ⁷Janssen Research & Development, LLC, Spring House, PA, ⁸University of Glasgow, Glasgow, United Kingdom
Background/Purpose: To evaluate the efficacy of ustekinumab (UST) by prior treatment exposure and disease duration in adult PsA patients (pts) in the Phase 3 trials…
Abstract Number: 1457 • 2017 ACR/ARHP Annual Meeting
Perioperative Management of Methotrexate and Tumor Necrosis Factor Inhibitor Combination Therapy in Rheumatoid Arthritis Patients
Hsin-Hsuan Juo^1,2 and Bernard Ng^1,3, ¹rheumatology, University of Washington, seattle, WA, ²rheumatology, VA Puget Sound Health Care System, seattle, WA, ³Rheumatology, VA Puget Sound Health Care System, seattle, WA
Background/Purpose: Rheumatoid arthritis (RA) patients have a higher frequency of requiring surgical procedures and worse surgical outcome. However, literature regarding post-surgical infectious outcome associated with…
Abstract Number: 1907 • 2017 ACR/ARHP Annual Meeting
Safety, Pharmacokinetics, and Efficacy of E6011, an Anti-Fractalkine Monoclonal Antibody, in a First-in-Patient Phase 1/2 Study on Rheumatoid Arthritis: 52-Week Results
Yoshiya Tanaka¹, Tsutomu Takeuchi², Hisanori Umehara³, Toshihiro Nanki⁴, Nobuyuki Yasuda⁵, Fumitoshi Tago⁶, Makoto Kawakubo⁶, Yasumi Kitahara⁶, Seiichiro Hojo⁶, Tetsu Kawano⁷ and Toshio Imai⁷, ¹The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, ²Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ³Division of Rheumatology and Immunology, Nagahama City Hospital, Shiga, Japan, ⁴Division of Rheumatology, Department of Internal Medicine, Toho University School of Medicine, Tokyo, Japan, ⁵KAN Research Institute, Inc., Tokyo, Japan, ⁶Eisai Co., Ltd., Tokyo, Japan, ⁷KAN Research Institute, Inc., Kobe, Japan
Background/Purpose: Fractalkine (CX3CL1/FKN) is a chemokine that regulates chemotaxis and adhesion of CX3C chemokine receptor 1 (CX3CR1)-expressing inflammatory cells. We previously presented the interim results…
Abstract Number: 2801 • 2017 ACR/ARHP Annual Meeting
Effects of Anti-IL17 Blockade with Secukinumab on Systemic and Local Immune Responses: A Mechanism-of-Action Study in Peripheral Spondyloarthritis
Leonieke van Mens¹, Marleen van de Sande², Silvia Menegatti³, Iris Blijdorp¹, Jet de Jong², Inka Fluri⁴, Talia Latuhihin¹, Arno van Kuijk⁵, Nataliya Yeremenko⁴ and Dominique Baeten¹, ¹AMC, Amsterdam Immunology and Rheumatology Center, Amsterdam, Netherlands, ²Clinical Immunology and Rheumatology, Amsterdam Rheumatology and immunology Center, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ³Immunology, Immunoregulation Unit, Institut Pasteur, Paris, France, ⁴Amsterdam Immunology and Rheumatology Center, Amsterdam, Netherlands, ⁵Reade, Amsterdam Immunology and Rheumatology Center, Amsterdam, Netherlands
Background/Purpose: IL-17A blockade is an effective therapy for AS and PsA, the prototypical forms of spondyloarthritis(SpA). How IL-17A blockade affects the systemic and local immune…
Abstract Number: 134 • 2017 ACR/ARHP Annual Meeting
Baseline Characteristics and Rates of Hospitalized Infections in Patients with Rheumatoid Arthritis Treated with Non-TNF Inhibitors in Denmark and Sweden
Kathrine Lederballe Grøn¹, Elizabeth V. Arkema², Bente Glintborg¹, Johan Askling³ and Merete Lund Hetland⁴, ¹The DANBIO registry and the Danish Departments of Rheumatology, Copenhagen, Denmark, ²Clinical Epidemiology Unit, Department of Medicine, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden, ³Unit of Clinical Epidemiology, Department of Medicine, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden, ⁴The DANBIO registry and the Danish Departments of Rheumatology, Glostrup, Denmark
Background/Purpose: Hospitalized infections during treatment with biologic disease modifying drugs (bDMARDs) in rheumatoid arthritis (RA) are a concern. This have mainly been studied in patients…
Abstract Number: 599 • 2017 ACR/ARHP Annual Meeting
Intravenous Golimumab in Adult Patients with Active Psoriatic Arthritis: Efficacy and Safety through Week 24
Arthur Kavanaugh¹, M. Elaine Husni², Diane D. Harrison³, Lilianne Kim³, Kim Hung Lo³ and Elizabeth C. Hsia⁴, ¹Medicine, University of California, San Diego, La Jolla, CA, ²Rheumatology, Cleveland Clinic, Cleveland, OH, ³Janssen Research & Development, LLC, Spring House, PA, ⁴Janssen Research & Development, LLC/University of Pennsylvania, Spring House/Philadelphia, PA
Background/Purpose: The GO-VIBRANT study was designed to evaluate the safety and efficacy of intravenous (IV) golimumab (GLM) in adult patients (pts) with active PsA (biologic-naïve).…
Abstract Number: 1471 • 2017 ACR/ARHP Annual Meeting
Flare Incidence and Predictive Factors in a Population of Patients with Rheumatoid Arthritis Under Optimised Treatment with Adalimumab and Infliximab
Amara Pieren¹, Dora Pascual-Salcedo², Pilar Aguado³, Gema Bonilla⁴, Eugenio De Miguel⁵, Irene Monjo⁶, Laura Nuño³, Diana Peiteado³, Alejandro Villalba³, Enrique Moral Coro⁴, C. Tornero⁷, Patricia Bogas⁴, Alejandro Balsa³ and Chamaida Plasencia-Rodriguez⁴, ¹Rheumatologyº, Hospital La Paz, Madrid, Spain, ²Immuno-Rheumatology Research group, La Paz University Hospital, Madrid, Spain, ³Rheumatology, La Paz University Hospital, Madrid, Spain, ⁴Hospital Universitario La Paz, Madrid, Spain, ⁵Rheumatology, University Hospital La Paz, IdiPaz, Madrid, Spain, ⁶Internal Medicine, Hospital Universitario La Paz, MADRID, Spain, ⁷Rheumatology, Rheumatology. La Paz University Hospital, Spain., Madrid, Spain
Background/Purpose:Anti-TNF has drastically changed the prognostic of the RA,carrying an important healthcare expense.This is why,optimisation seems a successful strategy that should not be linked to…
Abstract Number: 2014 • 2017 ACR/ARHP Annual Meeting
Reliability of 8-Joint Ultrasonography Scores in Follow up of Biological Therapy in Patients with Rheumatoid Arthritis
Ying-Chou Chen Sr., Division of Allergy, Immunology and Rheumatology, Chang Gung Memorial Hospital, Kaohsiung, Taiwan
Background/Purpose: The use of biological agents, or biologics, has revolutionized the treatment of rheumatoid arthritis (RA). Using power Doppler ultrasound, this study to evaluate the…

« Previous Page
1
…
5
6
7
8
9
…
26
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].